PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 177 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR Genetic Mechanisms Identified for Acquired Resistance to Non-Covalent BTK Inhibitors March 28, 2022 Por qué no voy a “superar” los efectos a largo plazo... July 20, 2021 Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in... August 22, 2024 A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in... September 28, 2023 Load more HOT NEWS Immunotherapy Combinations for Treating Metastatic Melanoma and Using Technology to Find... Amivantamab Plus Lazertinib Shows Superior Efficacy to Osimertinib in First-Line Treatment... EMA Recommends Extension of Therapeutic Indications for Pembrolizumab Cancer in My Community: Caring for Children With Cancer in Armenia
